The aim of this study was to evaluate visit-to-visit blood pressure (BP) variability in a cohort of patients with Alzheimer disease (AD) and healthy controls. Patients with clinically diagnosed mild or moderate AD and cognitively normal controls matched for age and sex were recruited and followed up for 6 months. To characterize the BP status of each individual, mean, maximum and minimum values, SD, and coefficient of variation were obtained for both systolic BP (SBP) and diastolic BP (DBP). Seventy AD patients and 140 controls were enrolled. No meaningful differences were found in prevalence or treatments of various vascular risk factors. AD patients had higher maximum and lower minimum values and greater SD and coefficient of variation of both SBP and DBP. Group differences in mean values were significant only for SBP. In the multiple logistic regression analysis, adjusted for confounding variables, all the indices related to BP variability were significantly associated with AD. Our results show that AD patients have a greater variability of both SBP and DBP in comparison with age-matched cognitive normal controls, suggesting potential implication in the pathogenesis or progression of the disease.
T he contribution of vascular disease in the pathogenesis and progression of Alzheimer disease (AD) is still a matter of debate. Understanding this relationship is relevant as it has been postulated that vascular disease may enhance cognitive impairment among AD patients. 1 As effective treatments in arresting or reversing cognitive decline among AD patients is currently lacking, the identification of potentially modifiable risk factors that might influence disease onset and progression are particularly relevant. The role of many vascular conditions and diseases in the pathogenesis of cognitive deterioration has been investigated, and to date evidence exists about the influence of blood pressure (BP) values on cognition. 2 Indeed, although recent evidence suggests that not only BP but even its variability may represent an independent risk factor for cerebrovascular diseases, 3, 4 few studies have addressed whether BP fluctuations may play a role in the context of dementia and cognitive impairment. The aim of this study was therefore to assess whether there was a difference in BP and visit-to-visit BP variability between patients affected by mild or moderate AD and cognitively normal age-matched and sex-matched controls.
METHODS

Participants
Patients with clinically diagnosed mild or moderate AD and cognitively normal controls matched for age and sex were recruited. Patients were selected from consecutive subjects referred to the dementia outpatient service of the Neurological Clinic of Universita`Politecnica delle Marche by general practitioners for progressive cognitive impairment from January 2011 to June 2012. Inclusion criterion of patients was a diagnosis of probable AD based on the National Institute of Neurological and Communicative Diseases and Stroke-Alzheimer's Disease and Related Disorders Association criteria. 5 Patients were selected after a careful evaluation of clinical and instrumental examinations by 2 neurologists with certified experience in managing patients with dementia. Controls were selected from consecutive subjects referred by general practitioners to our neurovascular laboratory for ultrasonographic evaluation of neck vessels as part of a primary prevention program for subjects older than 70 years. Baseline age, sex, ethnicity, years of education, clinical history, and medications were obtained from all subjects through proxy report and selfreport. Standard laboratory tests included complete blood count, serum electrolytes, glucose, blood urea nitrogen, vitamin B 12 , folate, uric acid, homocysteine, triglycerides, total and high-density lipoprotein cholesterol, and thyroid function tests. Low-density lipoprotein cholesterol concentrations were recalculated using the Friedewald formula. 6 Included subjects underwent a neurological examination, a neurosonological study of extracranial and intracranial vessels, and a cardiological evaluation including ECG and transthoracic or transesophageal echocardiography. Neuropsychological assessment explored all the main cognitive domains (general cognitive performance, long-term and short-term memory, attention, executive functions, language, problem solving, and constructive praxis) and excluded major psychiatric pathologies. Brain MRI images were obtained for all AD patients using a 1.5 T scanner with the spin-echo technique and T1weighted, T2-weighted, and fluid-attenuated inversionrecovery sequences to detect possible white matter lesions. These were graded according to Wahlund et al. 8 Only patients without vascular lesions (grade 0) or with small subcortical focal lesions defined as high signal intensity areas on T2-weighted images, but isointense with normal brain parenchyma on T1-weighted images and classified as grade I were included. Subjects with a clinical history of CVD, stepwise progression of cognitive impairment, focal neurological signs, severe subcortical leukoencephalopathy, cortical infarction, hemodynamically significant neck and large intracranial arteries stenosis or occlusion, and embolyzing cardiopathy were excluded.
Follow-up and BP Measurement
All patients received the acetylcholinesterase inhibitor donepezil (5 mg for 3 mo and thereafter 10 mg/daily). Management of vascular risk factors for both patients and controls was made in accordance with International Guidelines. 9 At baseline and every 30 days, from the beginning till the end of the 6-month follow-up period, each patient and control subject underwent a clinical evaluation, and BP was measured (3 times in the sitting position after a 5 min rest using a standard mercury sphygmomanometer, and recording the mean of the second 2 readings) by a neurologist blinded to the results of cognitive tests. To characterize the BP status of each individual, mean (the average of values), maximum and minimum values, SD, and variability defined through the coefficient of variation (CV) (SD Â 100/mean) were obtained for both systolic BP (SBP) and diastolic BP (DBP). At the end of the follow-up period, a complete neuropsychological assessment was repeated to confirm the initial diagnosis.
Standard Protocol Approvals, Registrations, and Patient Consents
The study was approved by the local ethical committee. All patients or caregivers included in the study gave written informed consent according to the Declaration of Helsinki.
Statistical Analysis
We evaluated the BP indices over a period of 6 months in a cohort of subjects affected by probable AD and matched controls. Descriptive statistics were computed on the demographic data, comorbidities, actual medication, and vascular risk factors and were expressed as mean ± SD for continuous variables or as the number (%) of subjects for categorical variables. The w 2 test and 2-sample t test, as appropriate, were used to test differences at the P < 0.05 level on each subject's characteristics. A logistic regression analysis was thus performed, before and after adjustment, for the effect of the potential confounding variables to evaluate the association of the different BP indices with the case/control status. The following potential confounders were considered: demographic characteristics (sex, age, and education), baseline MMSE score, vascular risk factors (hypertension, diabetes, smoking habits, and hyperlipidemia), and treatments (antihypertensives, statins, and antiplatelets). SPSS 13.0 package for Windows was used for statistical analysis.
RESULTS
A total of 210 subjects, 140 controls and 70 mild-tomoderate probable AD patients, were recruited. No statistically meaningful differences between patients and controls were found in vascular risk factors and treatments at baseline evaluation (Table 1) . MMSE score was 27.2 (± 2.76) in the control group and 18.98 (± 4.37) in AD patients (P < 0.001). No subject reported stroke or transient ischemic attack during the follow-up period. Neuropsychological evaluation at the end of the study confirmed the initial diagnosis in all AD patients.
In this study, AD subjects had a slight (5 mm Hg), but significantly lower mean SBP ( Table 2 ) without significant differences in DBP. When compared with controls, however, AD patients had greater variability in BP as evidenced by higher maximum and lower minimum values, and greater SD and CV of both SBP and DBP (Fig. 1 ). In the multiple logistic analysis, only maximum, maximum/minimum difference, SD, and CV values reached statistical significance for both SBP and DBP after adjustment for confounding variables (Table 3) .
DISCUSSION
There is a growing body of evidence that cardiovascular health may affect cognitive status including subjects with the clinical diagnosis of AD. 10, 11 The prevalence of a broad spectrum of cardiovascular risk factors and diseases, including heart failure, diabetes, hypertension, hypotension, hypercholesterolemia, coronary artery disease, valvular disease, heart failure, stroke, and atrial fibrillation are more common among the elderly, and many of these factors have been implicated as predictors of incident AD or associated with progression of the disese. [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] Although it is well established that high BP increases the risk of stroke and heart disease and decreases life expectancy, the interaction between BP measures and cognitive decline in AD remains underinvestigated. Large perspective cohort investigations or population-based studies find increased risk of AD-associated hypertension, particularly when hypertension is present in middle life. 22, 23 Other prospective studies have not confirmed, however, this increased risk of AD. 24, 25 These conflicting results could be partially attributable to the fact that both high and low BP can be detrimental for the brain. For example, low DBP levels have been related to an increased risk of AD in the elderly, particularly among users of antihypertensive drugs. 26 These findings suggest that the relationship between BP and cognitive function is more complicated than originally hypothesized. Furthermore, emerging evidence suggests that the predictive value of conventional BP measures for vascular disease decreases with increasing age, 27 and other parameters such as variability may be more informative. Visit-to-visit BP variability has recently been associated with silent cerebral injury, stroke, and worse performance in different cognitive domains and lower hippocampal volumes. 3, 28, 29 In our study, mean BP values did not differ strongly between groups, whereas all indices of pressure variability were significantly increased among AD patients. The strongest association was with the systolic parameters, and among them, the CV. These data reinforce the theorized link between neurovascular dysfunction and cognitive impairment. Higher visit-to-visit variability has been related to the damage of microvasculature with injury to endothelium and impairment of the functioning of smooth muscle cells of vessels, 30, 31 independent of mean BP. The consequent alterations in cerebral hemodynamics and blood flow can produce a detrimental effect on the neurovascular unit, that is, the system formed by neurons, astrocytes, and small vessels, representing the delicate junction between flow and neural metabolism. 32 Alterations in neurovascular coupling may lead to perturbed neuronal energy availability and possibly exacerbate cerebral hypometabolism to promote AD pathophysiology. 33 It has recently been confirmed that vascular and metabolic factors may directly lead to the deposition of b-amyloid (Ab) in the brain and the promotion of oxidative stress and inflammation. 1, 34, 35 In addition, it seems that Ab deposition may compromise cerebral endothelial cell function and thereby further limit the brain's capability to maintain adequate flow. 36 Indeed, BP variations may exert even greater effects on cerebral hemodynamics when cerebral autoregulation is impaired as common to the elderly or individuals with AD. 37, 38 Our study has a number of limitations that should be taken into consideration for a correct interpretation of results, such as the small number of patients involved, the lack of data on cerebral hemodynamics, and a simplified method for the assessment of BP. The relatively low number of patients included in our study did not allow us to explore the possible effect of the antihypertensive drugs regimens on BP variability. Furthermore, the antihypertensive therapy in Blood Pressure Variability in Alzheimer Disease patients with a diagnosis of hypertension was extremely variable. There is evidence that some classes of antihypertensive agents may reduce the risk and progression of AD more than others, 39, 40 leading to the possibility that BP variability could be pathologic. Moreover, we cannot define with certainty whether BP variability promotes cognitive deterioration or whether it is the result of central nervous system dysregulation accompanying dementia. For these reasons, our findings do not allow us to draw definitive conclusions but could stimulate speculations and suggest further investigations to better understand the relationship between BP, its variations, and AD. In this respect, further studies using other approaches including measurement of BP fluctuation by means of a 24-hour BP monitoring would be important. Further, assessing the presence and extent of orthostatic hypotension could increase our knowledge about the exact mechanisms linking hemodynamics alterations with cognitive deterioration in AD. 41 Our results suggest that not only the absolute value of BP but also its variability may need to be considered as a potential vascular risk factor involved in AD and may represent an uninvestigated, but promising therapeutic target. 
